<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glial inclusions containing the microtubule-associated protein tau are present in a variety of <z:hpo ids='HP_0011010'>chronic</z:hpo> neurodegenerative conditions </plain></SENT>
<SENT sid="1" pm="."><plain>We now report a rapid and time-dependent increase of tau immunoreactivity within oligodendrocytes after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in the rat </plain></SENT>
<SENT sid="2" pm="."><plain>The number of tau positive oligodendrocytes in the ipsilateral subcortical white matter increased six- to eightfold by 40 minutes after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>Tau was detected using antibodies that label both the N- and C-terminal of the protein, suggesting accumulation of full-length protein within these cells </plain></SENT>
<SENT sid="4" pm="."><plain>Pretreatment with the spin trap agent alpha-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-<z:chebi fb="0" ids="30355">tert-butyl</z:chebi>-nitrone (PBN)(100mg/kg) reduced the number of tau-positive oligodendrocytes by 55% in the subcortical white matter of the ischemic hemisphere compared with untreated animals at 40 minutes after MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, pretreatment with <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> MK-801 (0.5 mg/kg) or 2,3-dihydroxy-6-<z:chebi fb="13" ids="29785">nitro</z:chebi>-7-sulpfamoyl-benzo(f)<z:chebi fb="0" ids="36616">quinoxaline</z:chebi> (NBQX) (2 x 30 mg/kg), failed to reduce the number of tau-positive oligodendrocytes after 40 minutes of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The results indicate that oligodendrocytes respond rapidly to an ischemic challenge and that free radical-mediated mechanisms are involved in the cascade leading to increased tau immunoreactivity </plain></SENT>
</text></document>